Pretreatment biopsy analysis of DAB2IP identifies subpopulation of high-risk prostate cancer patients with worse survival following radiation therapy.

摘要: Decreased expression of tumor suppressor DAB2IP is linked to aggressive cancer and radiation resistance in several malignancies, but clinical survival data largely unknown. We hypothesized that pretreatment reduction would predict worse prostate cancer-specific (PCSS). Immunohistochemistry biopsies was scored by an expert genitourinary pathologist. Other endpoints analyzed include freedom from biochemical failure (FFBF), castration resistance-free (CRFS), distant metastasis-free (DMFS). Seventy-nine patients with NCCN-defined high-risk treated radiotherapy 2005 2012 at our institution were evaluated. Twenty-eight percent (22/79) revealed DAB2IP-reduction. The median follow up times 4.8 years 5.3 for the DAB2IP-reduced group DAB2IP-retained group, respectively. Patients reduced demonstrated outcome compared retaining DAB2IP, including FFBF (4-year: 34 vs. 92%; P < 0.0001), CRFS 58 96%; = 0.0039), DMFS 100%; 0.0006), PCSS (5-year: 83 0.0102). Univariate analysis showed T stage, N Gleason score statistically significant variables. Pretreatment status remained multivariable analyses. This study suggests about one-fourth men have decreased DAB2IP. subpopulation has a suboptimal response malignancy-specific following therapy androgen deprivation. loss may be genetic explanation observed differences characteristics resistance. Further into improving treatment this warranted.